/ COPY NUMBER VARIATIONS ON CHROMOSOME 15 DETECTED BY MOLECULAR KARYOTYPING IN PATIENTS WITH DEVELOPMENTAL DELAY AND CONGENITAL ANOMALIES

/

  • Branko Beronja Medicinski fakultet Univerziteta u Beogradu - student
  • Ana Đuranović
DOI: https://doi.org/10.5937/mp74-38783
Keywords: copy number variation, molecular karyotyping, chromosome 15, developmental delay

Abstract


Introduction: Global developmental delay (GDD) and congenital anomalies represent a heterogeneous group of medical conditions that may have a known genetic etiology. Molecular karyotyping is the gold standard for detecting copy number variations (CNV), and the first-line test in patients with GDD and congenital anomalies, with an average diagnostic yield of 15%. Chromosome 15 (C15) is one of the chromosomes on which CNV occur most frequently.

Aim: to analyze all detected non-polymorphic (significant) CNVs on C15 in  patients with GKR and/or congenital anomalies, estimate their share in the overall CNV detection rate of different pathogenicity classes, and present several illustrative cases.

Material and methods: In the total sample of 350 patients analyzed by molecular karyotyping technique, 92 with detected significant CNV were singled out. Then, all patients with variants on C15 were analyzed, which were further classified according to type, size, and clinical significance.

Results: In 11 patients, at least one significant CNV was detected on chromosome 15, which is 3.15% of the total sample and 11.96% on a sample of patients with significant CNV of any localization. In 72.7% cases CNV was described as pathogenic or likely pathogenic and in 27.3% as a variant of unknown significance. In the total detection rate of csCNV from all chromosomes 15.4%, the share of variations from C15 was 17.2% .

Conclusion: The detection rate of csCNVs on C15 in diagnostic yield of the molecular karyotypisation of the patients with GDD and congenital anomalies is 17.2%. , which confirms their significant portion in the etiology of these disorders.

References


  1. Belanger SA, Caron J. Evaluation of the child with global developmental delay and intellectual disability. Paediatr Child Health. 2018;23(6):403-19.

  2. Jones KL, Adam MP. Evaluation and diagnosis of the dysmorphic infant. Clin Perinatol. 2015;42(2):243-61, vii-viii.

  3. Moeschler JB, Shevell M, Committee on G. Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics. 2014;134(3):e903-18.

  4. Rosenfeld JA, Patel A. Chromosomal Microarrays: Understanding Genetics of Neurodevelopmental Disorders and Congenital Anomalies. J Pediatr Genet. 2017;6(1):42-50.

  5. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749-64.

  6. Ceylan AC, Citli S, Erdem HB, Sahin I, Acar Arslan E, Erdogan M. Importance and usage of chromosomal microarray analysis in diagnosing intellectual disability, global developmental delay, and autism; and discovering new loci for these disorders. Mol Cytogenet. 2018;11:54.

  7. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, et al. A copy number variation morbidity map of developmental delay. Nat Genet. 2011;43(9):838-46.

  8. Butler MG. Clinical and genetic aspects of the 15q11.2 BP1-BP2 microdeletion disorder. J Intellect Disabil Res. 2017;61(6):568-79.

  9. Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest. 2015;38(12):1249-63.

  10. Miller NL, Wevrick R, Mellon PL. Necdin, a Prader-Willi syndrome candidate gene, regulates gonadotropin-releasing hormone neurons during development. Hum Mol Genet. 2009;18(2):248-60.

  11. Buiting K, Williams C, Horsthemke B. Angelman syndrome - insights into a rare neurogenetic disorder. Nat Rev Neurol. 2016;12(10):584-93.

  12. Bossuyt SNV, Punt AM, de Graaf IJ, van den Burg J, Williams MG, Heussler H, et al. Loss of nuclear UBE3A activity is the predominant cause of Angelman syndrome in individuals carrying UBE3A missense mutations. Hum Mol Genet. 2021;30(6):430-42.

  13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.

  14. Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST, Working Group of the American College of Medical Genetics Laboratory Quality Assurance C. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. Genet Med. 2011;13(7):680-5.

  15. Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020;22(2):245-57.

  16. Silva M, de Leeuw N, Mann K, Schuring-Blom H, Morgan S, Giardino D, et al. European guidelines for constitutional cytogenomic analysis. Eur J Hum Genet. 2019;27(1):1-16.

  17. Nowakowska B. Clinical interpretation of copy number variants in the human genome. J Appl Genet. 2017;58(4):449-57.

  18. Spagnoli C, Schiavoni S, Rizzi S, Salerno GG, Frattini D, Koskenvuo J, et al. SPG6 (NIPA1 variant): A report of a case with early-onset complex hereditary spastic paraplegia and brief literature review. J Clin Neurosci. 2021;94:281-5.

  19. van Bon BW, Mefford HC, Menten B, Koolen DA, Sharp AJ, Nillesen WM, et al. Further delineation of the 15q13 microdeletion and duplication syndromes: a clinical spectrum varying from non-pathogenic to a severe outcome. J Med Genet. 2009;46(8):511-23.

  20. Chen CP, Lin SP, Chern SR, Wu PS, Chen YN, Chen SW, et al. Molecular cytogenetic characterization of an inv dup(15) chromosome presenting as a small supernumerary marker chromosome associated with the inv dup(15) syndrome. Taiwan J Obstet Gynecol. 2016;55(5):728-32.

  21. Rump P, Dijkhuizen T, Sikkema-Raddatz B, Lemmink HH, Vos YJ, Verheij JB, et al. Drayer's syndrome of mental retardation, microcephaly, short stature and absent phalanges is caused by a recurrent deletion of chromosome 15(q26.2-->qter). Clin Genet. 2008;74(5):455-62.

  22. Benbouchta Y, De Leeuw N, Amasdl S, Sbiti A, Smeets D, Sadki K, et al. 15q26 deletion in a patient with congenital heart defect, growth restriction and intellectual disability: case report and literature review. Ital J Pediatr. 2021;47(1):188.

  23. Okubo Y, Siddle K, Firth H, O'Rahilly S, Wilson LC, Willatt L, et al. Cell proliferation activities on skin fibroblasts from a short child with absence of one copy of the type 1 insulin-like growth factor receptor (IGF1R) gene and a tall child with three copies of the IGF1R gene. J Clin Endocrinol Metab. 2003;88(12):5981-8.

  24. Walenkamp MJ, de Muinck Keizer-Schrama SM, de Mos M, Kalf ME, van Duyvenvoorde HA, Boot AM, et al. Successful long-term growth hormone therapy in a girl with haploinsufficiency of the insulin-like growth factor-I receptor due to a terminal 15q26.2->qter deletion detected by multiplex ligation probe amplification. J Clin Endocrinol Metab. 2008;93(6):2421-


 

Published
2024/02/22
Issue
Vol. 74 No. 5 (2023): Medicinski podmladak
Section
Original Scientific Paper